Richard Scott Struthers, President & CEO at Crinetics Pharmaceuticals, Inc. (CRNX), sold 399,082 shares at $30.56 ($12.2M) on 2023-11-03, disclosed to the SEC on 2023-11-06.
Scheduled sale ($12.2M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.95 | 918 | $27K | 0.2% |
| 2 | $30.56 | 199,082 | $6.1M | 49.9% |
| 3 | $30.56 | 199,082 | $6.1M | 49.9% |
| Total | $30.56 avg | 399,082 | $12.2M | 100% |
| Filing → |
| CRNX | SELL | 2025-03-21 | $1.2M | — | Filing → |
| CRNX | SELL | 2024-12-04 | $576K | — | Filing → |
| CRNX | SELL | 2024-05-10 | $10.6M | — | Filing → |